SkinBioTherapeutics plc (LSE:SBTX) is drawing attention within the AIM market as investors weigh its latest company-specific developments against the wider outlook for skin health science, microbiome research and topical products. The central question on 13 October 2026 is whether the current investment narrative can …
EDX Medical develops and distributes diagnostic tests and related services. Its activities include the distribution of prostate cancer tests, a range of tests awaiting regulatory approval and more complex diagnostic products. The company was originally listed on the Aquis Growth Market in 2021, renamed …
EKF is a diagnostics business that makes point-of-care analysers and consumables, notably for haematology testing such as haemoglobin measurement, alongside a life sciences operation that provides contract manufacturing and fermentation services. It also produces beta-hydroxybutyrate (β-HB) reagents used in ketone testing. The life sciences …
Fusion was spun out of Queen's University Belfast in 2001. It provides antibody discovery, engineering, production and optimisation services to pharmaceutical and biotechnology customers developing therapeutic and diagnostic products. Its OptiMAL technology is a platform designed to support antibody discovery and was commercially launched …
Headquartered in Turku, Faron is a clinical-stage biopharmaceutical company listed on AIM and on Nasdaq First North Finland. Its approach targets Clever-1, a receptor on immune cells called macrophages, with the aim of reprogramming these myeloid cells to switch on the body's anti-tumour immunity. …
Feedback describes itself as a clinical infrastructure specialist. Its main product, Bleepa, is a platform that allows clinicians and care teams to work asynchronously on patient pathways, with the aim of reducing unnecessary outpatient appointments and speeding up decisions. The software is sold on …
ECO Animal Health develops and sells animal health products, with a long-established franchise in Aivlosin, an antibiotic used in pigs and poultry. It sells through a global network, with major markets in North America, Latin America, China and Japan, and South and Southeast Asia. …
The investment discussion centres on viral-vector development and manufacturing, with attention on CDMO contract wins, capacity use and cash conversion.
Renalytix is an artificial intelligence-enabled diagnostics business focused on chronic kidney disease. Its kidneyintelX.dkd test is an FDA-approved, Medicare-reimbursed prognostic test designed to assess early-stage risk in diabetic kidney disease. The shares trade on AIM and on the US OTCQB market. Medicare reimbursement is …
Smith & Nephew plc (LSE:SN.) is in focus on 13 October 2026 because investors are weighing company-specific developments alongside the wider direction of UK equities. The central question is whether its operating performance can translate into durable earnings, cash flow and shareholder value. For …